A 28-year-old man with cystic fibrosis presents for routine spirometry. His current FEV1 is 27% predicted, as shown in the diagram marked **A**. He is homozygous for the F508del mutation and has been on inhaled dornase alfa and hypertonic saline for 5 years but has never received CFTR modulator therapy. His sweat chloride is 95 mmol/L. Which of the following interventions would most significantly improve his FEV1 and reduce his risk of progressive lung function decline?
A. Initiation of long-term azithromycin for anti-inflammatory effect
B. Increased frequency of chest physiotherapy and airway clearance
C. Referral for lung transplant evaluation without further medical optimization
D. Elexacaftor/tezacaftor/ivacaftor (Trikafta) therapy
Explanation
Why Elexacaftor/tezacaftor/ivacaftor (Trikafta) therapy is right
The clinical anchor is that FEV1 <30% predicted is the traditional threshold for lung transplant referral in CF, but CFTR modulator therapy—specifically elexacaftor/tezacaftor/ivacaftor (Trikafta)—has revolutionized prognosis by producing a mean absolute FEV1 improvement of 13.8% within 4 weeks in patients with ≥1 F508del allele (Middleton NEJM 2019). This patient, homozygous for F508del with FEV1 27% predicted, is an ideal candidate for Trikafta. The modulator addresses the underlying CFTR dysfunction (defective chloride and bicarbonate transport), restores mucociliary clearance, reduces chronic neutrophilic inflammation, and decreases pulmonary exacerbations by 63%. This is the single most important intervention to prevent further FEV1 decline and defer or avoid transplantation. Sweat chloride would drop by ~40 mmol/L and BMI would improve, indicating restoration of CFTR function.
Why each distractor is wrong
Increased frequency of chest physiotherapy and airway clearance: While airway clearance is essential adjunctive therapy, it does not address the underlying CFTR dysfunction and cannot produce the magnitude of FEV1 improvement (13.8% absolute) seen with modulator therapy. It may slow decline but does not reverse it.
Initiation of long-term azithromycin for anti-inflammatory effect: Azithromycin is an important adjunctive anti-inflammatory agent that reduces exacerbations, but it does not correct CFTR function and does not produce the substantial FEV1 improvement required at this critical threshold. It is used alongside modulators, not instead of them.
Referral for lung transplant evaluation without further medical optimization: Although FEV1 <30% predicted historically met transplant referral criteria (Kerem 1992), modern practice mandates CFTR modulator therapy first to optimize lung function and defer transplantation. Referral without attempting modulator therapy would be premature and contrary to current guidelines (Harrison's 21e, Middleton NEJM 2019).
High-YieldNEET PG
FEV1 <30% predicted is no longer an automatic transplant referral in the modulator era—initiate CFTR modulators (Trikafta for F508del) first to potentially improve FEV1 by 13–14% and reduce exacerbations by 63%.
